^
    Back
    Association details:
    Biomarker:EGFR L858R
    Cancer:Lung Adenocarcinoma
    Drug:erlotinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

    Excerpt:
    When restricted to L858R mutation, PFS, RR, and DCR for gefitinib versus erlotinib were 8.1 and 8.5 months (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704), 57.5% and 46.3% (P = .174), and 81.3% and 79.1% (P = .744), respectively.
    DOI:
    10.1200/JCO.2015.63.4154
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

    Excerpt:
    ...previously detected deletion 19 or L858R EGFR mutation, female sex, history of never smoking, or Asian/Pacific Rim ethnicity (to be enrolled in the screening portion of trial)....
    Trial ID:
    NCT00567359
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Res Sq
    Title:

    Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

    Published date:
    10/13/2020
    Excerpt:
    Erlotinib showed significantly inferior OS than other TKIs (30.8 ± 3.3 in erlotinib vs. 39.1 ± 4.3 in afatinib vs. 48.4 ± 6.3 in gefitinib; p = 0.031) in patients with L858R.
    DOI:
    10.21203/rs.3.rs-91129/v1